Spravato Nasal Spray: Uses, Dosage & Side Effects

March 31, 2026

Spravato is one of the first rapid-acting antidepressant nasal sprays designed for treatment-resistant depression.

Spravato is a prescription medication formulated as an esketamine nasal spray, primarily used for individuals with treatment-resistant depression. The medication is different from other antidepressants, as it does not affect the levels of serotonin or norepinephrine but, instead, targets the glutamate system of the brain, providing rapid symptom relief.

This unique mechanism enables a faster improvement in symptoms, making Spravato a key treatment for individuals who are not responding well to other forms of treatment. This ability to act fast has made Spravato a breakthrough in contemporary mental health treatment.

Spravato treatment targets individuals who are experiencing depressive symptoms despite trying multiple medications. It also targets individuals with a diagnosis of major depressive disorder with suicidal thoughts, where fast relief from symptoms is a necessity.

As a form of esketamine, Spravato treatment takes the form of a nasal spray, which is given in a controlled environment for effectiveness and safety. This makes Spravato treatment a breakthrough in advanced psychiatric treatment due to its unique pharmacology.

What is Spravato?

Spravato is a prescription treatment that contains esketamine, which is used in a nasal spray form for the treatment of severe forms of depression. It is mainly used for the treatment of adults who have a condition known as treatment-resistant depression, which is a condition that has not improved with several antidepressant trials. As a Spravato nasal spray, this is a different form of treatment compared to the usual medication used for depression.

Unlike traditional antidepressants, Spravato works by targeting the NMDA receptor, which regulates glutamate activity in the brain, allowing for faster symptom relief. Due to the potential effects on perception and cognition, this treatment is only administered in a healthcare setting.

How Spravato Works (Mechanism of Action)

Spravato inhibits the NMDA (N-methyl-D-aspartate) receptor, a key regulator of glutamate, an important neurotransmitter involved in mood, cognition, and neural plasticity. Through this action, esketamine treatment assists in the restoration of connections that may be impaired in the brains of individuals who are depressed.

While traditional anti-depressant drugs act on the levels of serotonin and norepinephrine, Spravato, on the other hand, functions by means of a different action that assists in the improvement of neural communication and adaptability, thereby resulting in rapid anti-depressant action, which may be observed in the course of hours to days. It, however, has to be administered under clinical conditions due to its effect on cognition and perception.

Chemical & Pharmacological Data

Spravato contains esketamine, which is the S-enantiomer of ketamine. It is a non-competitive antagonist of the NMDA receptor. The medication is known for modulating glutamate systems, which are responsible for synaptic plasticity. The mechanism of action is thought to be central in treating depression, especially in patients who are resistant to other forms of treatment.

Spravato is different from other antidepressants, which are known for their serotonergic and noradrenergic systems. The medication, however, utilizes a different system, which is responsible for neural communication. The medication is fast-acting because, when it is administered intranasally, it is rapidly absorbed into the bloodstream.

The mechanism of action of Spravato is also responsible for improved neuronal signaling, which is thought to produce better results in treating depression. The medication, being an esketamine nasal spray, also contains dissociative properties, which are carefully monitored when it is administered. The mechanism of action of Spravato is different from other antidepressants, making it fast-acting.

Physical Form & Identification

Spravato is available in the form of a nasal spray solution, which is specifically designed for intranasal use in a clinical setting. It contains a fixed dose of esketamine, which is administered through a metered spray. It is a clear, colorless solution, which facilitates easy administration in a professional clinical setting. Each Spravato nasal spray contains a fixed dose of 28 mg of esketamine, which is administered depending on the treatment phase of the patient. Based on the esketamine dosage, the patient may need multiple devices for a single session. As Spravato is a derivative of ketamine, which is available in the form of a nasal spray, it has the potential for abuse. However, proper handling and administration of Spravato are done, which is only possible in a supervised setting. It is stored, dispensed, and administered only in a supervised environment, which is certified for the purpose. This is a controlled delivery system that enables healthcare providers to monitor the safety and efficacy of Spravato, which is administered for the treatment of depression.

Uses of Spravato

Spravato for Treatment-Resistant Depression

Spravato is generally used to treat adults who suffer from treatment-resistant depression, which means that the patients do not adequately respond to at least two different types of antidepressant therapies. This is considered to be one of the most difficult types of depression to treat, as it has the potential to cause long-term problems.

However, the Spravato treatment for depression provides patients with the opportunity to receive treatment that focuses on the glutamate levels, rather than the traditional neurotransmitters that are considered to be the cause of the illness. This allows the patients to feel relief from the symptoms of the illness, as the treatment has the potential to produce rapid results, providing relief to the patients in a matter of hours or days.

It has also been noted that the Spravato treatment for depression is generally given to patients along with another type of oral antidepressant, as this has the potential to produce the best results for the patients. The treatment is also given to the patients under medical supervision, particularly during the early stages of the treatment.

Spravato for Major Depressive Disorder with Suicidal Thoughts

Spravato has also been approved for the treatment of adults who suffer from major depressive disorder, particularly if they are accompanied by acute suicidal thoughts and behaviors. This is a serious medical condition that requires immediate and effective treatment. It is important to note that, in these situations, the effects of traditional antidepressant drugs may not be apparent for several weeks, which may not be sufficient in acute clinical situations. Spravato, as an esketamine nasal spray, offers the advantage of fast-acting action, which can be particularly important in the treatment of individuals who suffer from depressive conditions, as it may be able to reduce the symptoms of the condition more quickly. It should be noted that, although Spravato offers the advantage of fast action, the treatment of individuals who suffer from acute suicidal thoughts and behaviors is not sufficient on its own and must be part of the overall treatment plan. Spravato is administered to patients in certified healthcare facilities because of its impact on the perception, cognition, and blood pressure of the individual, as this allows the side effects to be managed while maximizing the overall benefit of the treatment.

Limitations and Considerations of Spravato Use

Though using Spravato for depression can lead to quick relief from symptoms, it is also important to understand that it is not capable of preventing relapse or suicidal tendencies. This suggests that it is possible for patients using Spravato for depression to require psychiatric care for the improvement of their condition.

The other limitation of using Spravato for depression is that it is usually required to be taken under strict supervision. This indicates that it is not possible for patients using Spravato for depression to do so at home. This is because it is evident that it can lead to several side effects, including sedation, dissociation, and increased blood pressure.

In addition, Spravato is not indicated for use in pediatric patients and should be used with caution in certain medical conditions. These limitations emphasize the need for careful patient selection in considering esketamine therapy as part of a comprehensive treatment plan for mental health conditions.

Boxed Warning: Important Safety Risks

Spravato also poses considerable safety risks that necessitate strict medical supervision. The most important safety risks associated with the drug are:

Sedation and loss of consciousness: Spravato may cause drowsiness or loss of consciousness in the user.
Dissociation: Spravato may cause users to have a sense of detachment from reality.
Respiratory depression: Spravato may cause a reduction in respiratory rate.
Abuse and misuse potential: Being a Schedule III controlled substance, Spravato has a high risk of dependence.
Suicidal thoughts and behaviors: Being an antidepressant drug, Spravato may cause suicidal thoughts in some users, especially the younger population.

Therefore, the user must be monitored for at least 2 hours after each dose in a certified healthcare setting.

Dosage & Administration

Recommended Dosage Schedule

The dosage of Spravato depends on the stage of treatment and how the patient responds. It is usually given in two phases:

Initial phase (first 4 weeks): – Administered twice weekly
– Aims for rapid symptom improvement
Maintenance phase: – Administered once weekly or every two weeks
– Frequency reduced after stabilization
Typical dose: – 56 mg or 84 mg per session
Each device delivers 28 mg, so multiple devices may be used.

The goal of Spravato treatment is to use the lowest effective dose that maintains improvement while minimizing side effects.

Important Pre-Administration Instructions

Before receiving the Spravato treatment, certain precautions should be taken to help prevent side effects from occurring, which are as follows:

Avoid food intake for at least 2 hours before receiving the treatment
Avoid the intake of liquids for at least 30 minutes before receiving the treatment
If you are currently using nasal sprays, such as decongestants or corticosteroids, you should use these at least 1 hour before receiving the treatment
Inform your doctor about your current medications and health conditions

These steps help reduce nausea and ensure optimal absorption of the medication.

How Spravato is Administered (Step-by-Step)

Spravato is given as an esketamine nasal spray in a clinical setting. It is not used at home.

Step-by-step process:

The patient attends a healthcare facility
Blood pressure is checked before administration
The patient uses the antidepressant nasal spray under supervision
The dosage may require the use of more than one spray device depending on the prescription
The healthcare provider observes the patient during the administration

What Happens After Taking Spravato

After receiving Spravato treatment, patients are closely monitored for safety.

Patients are supposed to stay in the clinic for a minimum of 2 hours
Blood pressure is closely monitored
Doctors closely observe for any side effects such as:
Dizziness
Dissociation
Drowsiness

Missed Dose or Treatment Session

If a patient does not attend a scheduled session for a Spravato treatment, the next steps depend on the symptoms as follows:

If symptoms are stable → continue with the existing schedule
If symptoms are worse → doctor may consider reverting to a higher frequency of dosing
The adjustments are made based on clinical judgment

Patients should not try to adjust the schedules on their own.

Important Safety Instructions

Do not drive or operate machinery until the following day
Arrange for a ride home after each session
Avoid alcohol and sedatives unless prescribed by a doctor
Always follow the advice of a doctor

Due to these safety precautions, Spravato nasal spray is available only under specialized treatment programs in medical facilities.

Side Effects of Spravato

Spravato has been known to cause a number of side effects. Most of these side effects occur immediately after taking the drug. However, they tend to be temporary and may go away within a short period. The common side effects of Spravato include:

Dissociation or feeling detached from reality
Dizziness or a spinning sensation
Drowsiness or sedation
Nausea and vomiting
Increased blood pressure
Anxiety or restlessness
Headache
Reduced sensitivity to touch or other sensations
Feeling “drunk” or altered perception

The side effects of Spravato tend to be related to how the drug works on the brain. Since esketamine antidepressant nasal spray works on perception and brain function, patients tend to be under clinical observation to ensure they get over these side effects.

Serious Side Effects of Spravato

Though not common, these adverse effects can also be severe. Therefore, patients taking Spravato for depression should be informed of the following severe adverse effects of the medication:

Significant increase in blood pressure lasting several hours after administration
Severe dizziness or fainting
Difficulty breathing or signs of an allergic reaction (such as swelling of the face, lips, or throat)
Intense sedation or inability to stay awake
Confusion, disorientation, or memory disturbances
Hallucinations or unusual sensory experiences
Worsening depression or emergence of suicidal thoughts
Unusual changes in mood or behavior, including agitation or irritability

In all these instances, medical attention should be sought immediately.

Important Safety Note

This is not a complete list of side effects. Other side effects may also occur. Any person receiving Spravato treatment should consult their healthcare provider for medical information about side effects.

As the medication has an impact on both the physical and mental condition of the body, the occurrence of new symptoms should be reported to the doctor. This includes the mood, behavior, and overall condition of the body.

Patients should seek medical attention if severe side effects are experienced. Reporting side effects will improve the safety of Spravato for the treatment of depression.

Clinical & Research Applications

Spravato has received considerable attention in recent times because of its novel mechanism of action and its fast-acting antidepressant properties. As a nasal spray formulation of esketamine, Spravato marks a departure from other antidepressants, which act on serotonin, norepinephrine, or other neurotransmitter systems, in favor of glutamatergic neurotransmission. This has opened new therapeutic possibilities for the management of mood disorders, especially in individuals who are non-responsive to conventional therapies.

Spravato, in clinical practice, is used for the management of refractory depression and major depressive disorder with suicidal ideation. Its fast-acting properties are particularly useful in acute situations where prompt relief from symptoms is urgently needed. Other conditions, which are currently in the pipeline for the use of Spravato, are bipolar depression and post-traumatic stress disorder (PTSD).

According to research, Spravato, as a treatment for depression, has the potential to aid in the restoration of synaptic connectivity, as well as neural plasticity, which are compromised in the chronic depressive state. Even though the results are promising, the long-term outcome and the wider implications are subject to further research. As research into the subject continues, esketamine therapy will continue to play a vital role in the treatment of psychiatric conditions.

Forensic & Regulatory Considerations

Spravato is a Schedule III controlled substance, which indicates it can lead to abuse and dependence. Since it is a derivative of ketamine, a substance known for abuse, it is heavily regulated for safe use in a medical environment.

In order to ensure safe use, Spravato or ketamine spray is only provided through a special distribution system called the Risk Evaluation and Mitigation Strategy (REMS) program. This program requires special certification of healthcare facilities and providers, as well as administration of the medication within a clinical environment. This is done to ensure safe use of Spravato.

Furthermore, Spravato is not intended for use outside of a clinical environment, and patients are required to stay under supervision for a period of time following administration. As it relates to forensic science, it is clear that it is a controlled substance, and it is vital to follow proper documentation, patient evaluation, and legal requirements when prescribing esketamine nasal spray.

Warnings & Monitoring

Spravato has several safety precautions due to its impact on the central nervous system and cardiovascular system. Due to the potential risks, Spravato treatments is only given in a certified healthcare environment under strict supervision.

Patients need to be monitored for a period of at least two hours after taking the drug, as there is a potential for sedation and dissociation

Checking the blood pressure of the patient is necessary, as Spravato has the potential to temporarily raise blood pressure
Patients need to avoid operating heavy machinery until the next day after proper rest
There is a potential risk of misuse or dependence, as Spravato is related to ketamine
Precautions are necessary for individuals with cardiovascular and neurological conditions
Not recommended for certain high-risk populations without proper evaluation

Esketamine therapy is offered through a series of treatment programs, considering the potential risks involved, for maximum safety and effectiveness.

Cognitive and Functional Impairment

Spravato may affect the following on a temporary basis:

Attention and concentration,
Judgment and decision-making
reaction time and motor coordination

It is recommended that patients avoid activities that require full alertness, such as driving and the use of machinery, until the day after treatment.

Urinary and Bladder Effects

Long-term or repeated use of ketamine-related drugs is associated with urinary symptoms such as:

Frequent urination
Painful urination
Irritation of the bladder

Though not common, patients should inform their healthcare provider if they experience any urinary symptoms during Spravato treatments.

Drug Interactions

Spravato can also interact with other drugs, which can increase the risk of side effects or complications. The important interactions are as follows:

Central nervous system (CNS) depressants

(e.g., benzodiazepines, opioids, alcohol) → May increase sedation and respiratory depression

Psychostimulants (e.g., amphetamines) → May increase blood pressure
Monoamine oxidase inhibitors (MAOIs) → May increase blood pressure

Patients should always inform the healthcare provider about the drugs they are currently taking before they are given the treatment with Spravato.

Contraindications

However, Spravato is not appropriate for all patients and must be avoided in patients with specific medical conditions where its effects can result in substantial risk to patients. Since treatment with Spravato can result in high blood pressure and effects on the central nervous system, appropriate patient selection is critical before treatment is initiated. Spravato is contraindicated for use in patients with the following medical conditions:

Aneurysmal vascular diseases, including thoracic and abdominal aortic aneurysms
Arteriovenous malformations
History of intracerebral hemorrhage
Conditions associated with increased intracranial pressure
Uncontrolled high blood pressure and cardiovascular instability
Hypersensitivity to esketamine, ketamine, and any components of the formulation, in addition, caution is advised in patients with significant cardiovascular disease
History of stroke or other cerebrovascular disorders
Severe hepatic impairment
psychiatric conditions involving psychosis

Given these risks, it is necessary to conduct an extensive medical examination before administering Spravato treatment. Healthcare practitioners must evaluate each patient’s medical history and condition to ascertain whether the benefits outweigh the risks.

Use in Pregnancy and Lactation

Pregnancy: Spravato has the potential to cause damage to the developing fetus based on animal studies. Spravato should be used during pregnancy only if its potential benefits outweigh its potential risks.
Breastfeeding: Breastfeeding is contraindicated during treatment with Spravato because the drug has the potential to be excreted in breast milk.
Reproductive considerations: Child-bearing women should discuss reproductive plans and birth control with their healthcare provider.

Frequently Asked Questions

How quickly does Spravato work?

Spravato is also notable for its fast-acting effects, as opposed to other antidepressants. While other depression medications can take weeks to manifest their effects, the effects of Spravato for depression can manifest within a few hours or days. This makes it especially useful for treating severe depression, especially for those who have suicidal tendencies, as symptom management is critical in the short term.

Is Spravato addictive?

Due to its chemical similarity to ketamine, Spravato has the possibility of causing dependence or abuse. However, this is greatly reduced because it is administered in a controlled environment. The patients do not have to take the drug at home, and this makes Spravato treatment safe.

Can it be used at home?

The answer is no, Spravato nasal spray cannot be used at home. It must be used in a healthcare facility. This is because of the side effects, which include sedation, dissociation, and increased blood pressure. All these side effects must be monitored for at least two hours after each dose.

Is it covered by insurance?

The coverage of the ketamine nose spray using Spravato varies depending on the country and the insurance plan, as well as the condition of the patient. In the case of treatment-resistant depression, many insurance plans cover the treatment, although prior authorization is required in this case.

Conclusion

Spravato represents a significant advancement in the treatment of depression, especially for patients who have not responded to other forms of treatment. Its unique form as an esketamine nasal spray provides a new way to treat depression, acting on the glutamate system in the brain to bring quicker and more effective relief from depression than traditional antidepressants.

Although treatment with Spravato has been found to be successful, it is not without its drawbacks. However, it is proving to be a valuable tool for dealing with complex and treatment-resistant depression.

As more is learned about this treatment, Spravato for depression is likely to become more and more important in psychiatric care. Used responsibly and within a comprehensive treatment plan for mental health, it has the potential to greatly help patients and improve their quality of life.

Disclaimer

The information provided is for educational and informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. It is to be understood that the information provided is accurate to the best of the knowledge at the time of writing.

It is always advisable to consult a qualified medical professional before initiating or altering any course of treatment, including Spravato treatment. It is also to be understood that the effects of drugs can differ from person to person, and only a qualified medical professional can recommend the best course of action for a patient based on the patient’s medical history and condition.

The use of Spravato for depression should be assessed and monitored properly, and the information provided should be used responsibly in the context of the advice of a medical professional, as any concerns should be taken care of by a medical professional.